+

WO2009043593A1 - Thérapie de combinaison utilisant la mémantine et les glitazones - Google Patents

Thérapie de combinaison utilisant la mémantine et les glitazones Download PDF

Info

Publication number
WO2009043593A1
WO2009043593A1 PCT/EP2008/008400 EP2008008400W WO2009043593A1 WO 2009043593 A1 WO2009043593 A1 WO 2009043593A1 EP 2008008400 W EP2008008400 W EP 2008008400W WO 2009043593 A1 WO2009043593 A1 WO 2009043593A1
Authority
WO
WIPO (PCT)
Prior art keywords
memantine
pioglitazone
salt
pharmaceutically acceptable
disease
Prior art date
Application number
PCT/EP2008/008400
Other languages
English (en)
Inventor
Birgit Anderegg
Alexander Gebauer
Kate Gilling
Andreas Gravius
Claudia Jatzke
Sebastian Krempien
Bernd Otterbach
Original Assignee
Merz Pharma Gmbh & Co. Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co. Kgaa filed Critical Merz Pharma Gmbh & Co. Kgaa
Publication of WO2009043593A1 publication Critical patent/WO2009043593A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the present invention relates to combinations comprising memantine and a glitazone and the use of such combinations in the treatment of neurodegenerative diseases and/or to provide neuroprotection.
  • NMDA receptor antagonists potentially have a wide range of therapeutic applications in numerous CNS disorders such as acute neurodegeneration (e.g., associated with stroke and trauma), chronic neurodegeneration (e.g., associated with Parkinson's disease, Alzheimer's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS)), epilepsy, drug dependence, depression, anxiety, and chronic pain (for reviews see: Parsons et al., Drug News Perspect, 1998, 11 :523-533; Parsons et al., 1999, supra; Jentsch and Roth, Neuropsychopharmacology, 1999, 20: 201-205; Dobte, Therapie, 1995, 50: 319-337), Functional inhibition of NMDA receptors can be achieved through actions at different recognition sites within the NMDA receptor complex, such as: the primary transmitter site (competitive), the phencyclidine site located inside the cation channel (uncompetitive), the polyamine modulatory site and the strychnine-insensitive, co-agonistic, allosteric
  • excitatory neurotransmitter glutamate plays an important role in the pathophysiology (as opposed to etiology) of neurodegenerative diseases such as Alzheimer's disease, Parkinsons's disease, and amyotrophic lateral sclerosis.
  • About 70% of all excitatory synapses in the CNS are stimulated by glutamate, and dysfunctional, chronic release of glutamate can produce a prolonged excitatory effect via glutamate receptor activation. This prolonged activation is
  • Memantine (1-amino-3,5-dimethyl adamantane, disclosed, e.g., in U.S. Patents No. 4,122,193; 4,273,774; 5,061 ,703) is a systemically-active uncompetitive NMDA receptor antagonist having moderate affinity for the receptor and strong voltage dependency and rapid blocking/unblocking kinetics.
  • Memantine has been shown to be useful in alleviation of various progressive neurodegenerative disorders such as dementia in patients with moderate to severe Alzheimer's disease, Parkinson's disease, and spasticity (see, e.g., U. S. Patents No.
  • Memantine has also been suggested to be useful in the treatment of AIDS dementia (U.S. Patent No. 5,506,231), neuropathic pain (U.S. Patent No. 5,334,618), cerebral ischemia (U.S. Patent No. 5,061,703), epilepsy, glaucoma, hepatic encephalopathy, multiple sclerosis, stroke, and tardive dyskinesia (Parsons et al., 1999, supra). Memantine is currently approved in Europe and the United States for the treatment of Alzheimer's disease.
  • peroxisome proliferator-activated receptor- ⁇ (PPAR ⁇ ) agonists such as the thiazolidinedione class of anti-diabetic agents (i.e., glitazones)
  • PPAR ⁇ peroxisome proliferator-activated receptor- ⁇
  • glitazones the thiazolidinedione class of anti-diabetic agents
  • this activity may be associated with activation of PPAR ⁇ , which, in turn, inhibits inflammatory responses in the brain and negatively modulates amyloidogenesis (Landreth, Experimental Neurology, 2006, 199, 245-248).
  • rosiglitazone therapy improves cognition in some Alzheimer's patients (Watson, et al., Am. J. Geriatr. Psychiatry, 2005, 13, 950- 958; Risner, et al., Pharmacogenomics Journal, 2006, 6, 246-254).
  • rosiglitazone Pedersen, et al., Exp. Neurology, 2006, 199, 265-273
  • pioglitazone Heneka, et al., Brain, 2005, 128, 1442-1453 exhibit beneficial therapeutic effects in a mouse model for Alzheimer's disease.
  • Pioglitazone and rosiglitazone also exhibit protective effects in a rat model of mild forebrain ischemia reperfusion injury. (Collino, et al., Eur. J. Pharmacol., 2006, 530, 70-80).
  • PPAR ⁇ agonists have also exhibited activity in animal models' of stroke, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis, which activity may be attributable to the anti-inflammatory actions associated with PPAR ⁇ agonists (Landreth, Experimental Neurology, 2006, 199, 245-248).
  • Pioglitazone has been shown to bind to MitoNEET (Colca, et al., Am. J. Physiol. Endocrinol. Metab., 2004, E252-E260) a protein located within the mitochondrial membrane, which protein has been recently characterized (Paddock, et al., PNAS, 2007, 104, 14342-14347). Pioglitazone has been shown to induce mitochondrial biogenesis and to reduce mitochondrial oxidative stress in a neuron- like cell line (Ghosh, et al., MoI. Pharmacol., 2007, 71, 1695-1702), and rosiglitazone has also been shown to stimulate mitochondrial biogenesis in mouse brain (Roses, et al., supra).
  • the present invention relates to combinations comprising memantine and a glitazone and the use of such combinations in the treatment of neurodegenerative diseases and/or to provide neuroprotection.
  • a further aspect of the invention relates to combinations comprising memantine and a glitazone and the use of such combinations in the treatment of neurodegenerative diseases, including Alzheimer's disease, stroke, multiple sclerosis, progressive supranuclear palsy, schizophrenia, Huntington's disease, and amyotrophic lateral sclerosis, and/or to provide neuroprotection.
  • neurodegenerative diseases including Alzheimer's disease, stroke, multiple sclerosis, progressive supranuclear palsy, schizophrenia, Huntington's disease, and amyotrophic lateral sclerosis, and/or to provide neuroprotection.
  • a further aspect of the invention relates to combinations comprising memantine and a glitazone selected from pioglitazone, troglitazone, rosiglitazone, ciglitazone, englitazone, darglitazone, rivoglitazone, isaglitazone, KRP 297, T 174, and NP 0110, and the use of such combinations in the treatment of neurodegenerative diseases, including Alzheimer's disease, stroke, multiple sclerosis, progressive supranuclear palsy, schizophrenia, Huntington's disease, and amyotrophic lateral sclerosis, and/or to provide neuroprotection.
  • neurodegenerative diseases including Alzheimer's disease, stroke, multiple sclerosis, progressive supranuclear palsy, schizophrenia, Huntington's disease, and amyotrophic lateral sclerosis, and/or to provide neuroprotection.
  • a further aspect of the invention relates to combinations comprising memantine and a glitazone selected from pioglitazone, troglitazone, rosiglitazone, ciglitazone, englitazone, darglitazone, rivoglitazone, isaglitazone, KRP 297, T 174, and NP 0110, and the use of such combinations in the treatment of Alzheimer's disease.
  • a further aspect of the invention relates to combinations comprising memantine and pioglitazone as well as a method of treating an individual diagnosed with Alzheimer's disease, comprising administering to the individual an effective amount of a combination of memantine and pioglitazone.
  • a further aspect of the invention relates to the use of a combination comprising memantine and a glitazone for the manufacture of a medicament for the treatment of neurodegenerative diseases and/or to provide neuroprotection.
  • a further aspect of the invention relates to the use of a combination comprising memantine and a glitazone for the manufacture of a medicament for the treatment of Alzheimer's disease, stroke, multiple sclerosis, and amyotrophic lateral sclerosis.
  • a further aspect of the invention relates to the use of a combination comprising memantine and a glitazone selected from pioglitazone, troglitazone, rosiglitazone, ciglitazone, englitazone, darglitazone, rivoglitazone, isaglitazone, KRP 297, T 174, and NP 0110, for the manufacture of a medicament for the treatment of neurodegernative diseases, including Alzheimer's disease, stroke, multiple sclerosis, and amyotrophic lateral sclerosis.
  • a glitazone selected from pioglitazone, troglitazone, rosiglitazone, ciglitazone, englitazone, darglitazone, rivoglitazone, isaglitazone, KRP 297, T 174, and NP 0110
  • a further aspect of the invention relates to the use of a combination comprising memantine and a glitazone selected from pioglitazone, troglitazone, rosiglitazone, ciglitazone, englitazone, darglitazone, rivoglitazone, isaglitazone, KRP 297, T 174, and NP 0110, for the manufacture of a medicament for the treatment of Alzheimer's disease.
  • a further aspect of the invention relates to the use of a combination comprising memantine and pioglitazone for the manufacture of a medicament for treatment of an individual diagnosed with Alzheimer's disease.
  • An additional aspect of the invention relates to a pharmaceutical composition for the treatment of neurodegenerative diseases and/or to provide neuroprotection comprising a therapeutically effective amount of a combination of memantine and a glitazone, and at least one pharmaceutically acceptable excipient.
  • a further aspect of the invention relates to a pharmaceutical composition for the treatment of neurodegenerative diseases, including Alzheimer's disease, stroke, multiple sclerosis, progressive supranuclear palsy, schizophrenia, Huntington's disease, and amyotrophic lateral sclerosis, and/or to provide neuroprotection, comprising a therapeutically effective amount of a combination of memantine and a glitazone, including pioglitazone, troglitazone, rosiglitazone, ciglitazone, englitazone, darglitazone, rivoglitazone, isaglitazone, KRP 297, T 174, and NP 0110, and at least one pharmaceutically acceptable excipient.
  • neurodegenerative diseases including Alzheimer's disease, stroke, multiple sclerosis, progressive supranuclear palsy, schizophrenia, Huntington's disease, and amyotrophic lateral sclerosis
  • a further aspect of the invention relates to a pharmaceutical composition for the treatment of Alzheimer's disease comprising a therapeutically effective amount of a combination comprising memantine and pioglitazone, and at least one pharmaceutically acceptable carrier or excipient.
  • a further aspect of the invention relates to a pharmaceutical composition for the treatment of Alzheimer's disease comprising a therapeutically effective amount of a combination comprising memantine and pioglitazone in an immediate or modified release formulation.
  • composition comprising two active agents (e.g., a pharmaceutical composition comprising memantine and pioglitazone) or two separate pharmaceutical compositions, each comprising an active agent (e.g. a pharmaceutical composition comprising memantine or pioglitazone), to be administered conjointly.
  • active agents e.g., a pharmaceutical composition comprising memantine and pioglitazone
  • disjoint administration is used to refer to administration of memantine and a glitazone compound (for example, pioglitazone) simultaneously in one composition, or simultaneously in different compositions, or sequentially.
  • memantine and the second active agent must be administered separated by a time interval which still permits the resultant beneficial effect for treating a neurodegenerative disease (such as Alzheimer's disease) in a mammal.
  • neurodegenerative diseases includes Alzheimer's disease, stroke, multiple sclerosis, progressive supranuclear palsy, schizophrenia, Huntington's disease, and amyotrophic lateral sclerosis.
  • Memantine (1-amino-3,5-dimethyl adamantane) is disclosed in U.S. Patent Nos. 4,122,193; 4,273,774; 5,061 ,703, the subject matter of which is hereby incorporated by reference.
  • Memantine may be used according to the invention in the form of any of its pharmaceutically acceptable salts (e.g., memantine hydrochloride), solvates, isomers, conjugates, prodrugs, metabolites, and derivatives, any references to memantine in this description should be understood as also referring to such salts, solvates, isomers, conjugates, prodrugs, metabolites, and derivatives.
  • glitazone refers to the thiazolinedione class of antidiabetic agents.
  • examples of glitazones include pioglitazone, troglitazone, rosiglitazone, ciglitazone, englitazone, darglitazone, rivoglitazone, isaglitazone, KRP 297, T 174, and NP 0110.
  • Pioglitazone (5-((4-(2-(5-ethyl-pyridin-2-yl)-ethoxy]-benzyl ⁇ -thiazolidine-2,4- dione) is disclosed in U.S. Patent No. 4,687,777, the subject matter of which is hereby incorporated by reference.
  • Pioglitazone may be used according to the invention in the form of any of its pharmaceutically acceptable salts (e.g., pioglitazone hydrochloride), solvates, isomers, conjugates, prodrugs, metabolites, and derivatives, any references to pioglitazone in this description should be understood as also referring to such salts, solvates, isomers, conjugates, prodrugs, metabolites, and derivatives.
  • pharmaceutically acceptable salts e.g., pioglitazone hydrochloride
  • solvates isomers
  • conjugates conjugates
  • prodrugs metabolites
  • derivatives any references to pioglitazone in this description should be understood as also referring to such salts, solvates, isomers, conjugates, prodrugs, metabolites, and derivatives.
  • Troglitazone (5-(4-(6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-yl-methoxy)- benzyl)-thiazolidine-2,4-dione) is disclosed in US Patent No. 4,572,912, the subject matter of which is hereby incorporated by reference.
  • Troglitazone may be used according to the invention in the form of any of its pharmaceutically acceptable salts, solvates, isomers, conjugates, prodrugs, metabolites, and derivatives, any references to troglitazone in this description should be understood as also referring to such salts, solvates, isomers, conjugates, prodrugs, metabolites, and derivatives.
  • Rosiglitazone (5-(4-(2-(Methyl-pyridin-2-yl-amino)-ethoxy)-benzyl)-thiazolidine- 2,4-dione) is disclosed in U.S. Patent Nos. 5,002,953 and 5,741 ,803, the subject matter of which is hereby incorporated by reference.
  • Rosiglitazone may be used according to the invention in the form of any of its pharmaceutically acceptable salts (e.g., rosiglitazone maleate), solvates, isomers, conjugates, prodrugs, metabolites, and derivatives, any references to rosiglitazone in this description should be understood as also referring to such salts, solvates, isomers, conjugates, prodrugs, metabolites, and derivatives.
  • pharmaceutically acceptable salts e.g., rosiglitazone maleate
  • solvates isomers, conjugates, prodrugs, metabolites, and derivatives
  • any references to rosiglitazone in this description should be understood as also referring to such salts, solvates, isomers, conjugates, prodrugs, metabolites, and derivatives.
  • Ciglitazone (5-(4-(1-Methyl-cyclohexylmethoxy)-benzyl)-thiazolidine-2,4-dione) is disclosed in US Patent No. 4,287,200, the subject matter of which is hereby incorporated by reference. Ciglitazone may be used according to the invention in the form of any of its pharmaceutically acceptable salts, solvates, isomers, conjugates, prodrugs, metabolites, and derivatives, any references to ciglitazone in this description should be understood as also referring to such salts, solvates, isomers, conjugates, prodrugs, metabolites, and derivatives.
  • Englitazone (5-((2-benzyl-3,4-dihydro-2H-1-benzopyran-6-yl)-methyl)- thiazolidine-2,4-dione) is disclosed in Clark, et al. (J. Med. Chem., 1991, 34, 319- 325). Englitazone may be used according to the invention in the form of any of its pharmaceutically acceptable salts (e.g. englitazone sodium salt), solvates, isomers, conjugates, prodrugs, metabolites, and derivatives, any references to englitazone in this description should be understood as also referring to such salts, solvates, isomers, conjugates, prodrugs, metabolites, and derivatives.
  • pharmaceutically acceptable salts e.g. englitazone sodium salt
  • solvates isomers, conjugates, prodrugs, metabolites, and derivatives
  • any references to englitazone in this description should be understood as also referring to such salts, solvates
  • Darglitazone (5-(4-(3-(5-methyl-2-phenyl-4-oxazolyl)propionyl)- benzyl)thiazolidine-2,4-dione) is disclosed in Hulin, et al. (J. Med. Chem., 1992, 35, 1853-1864)
  • Darglitazone may be used according to the invention in the form of any of its pharmaceutically acceptable salts, solvates, isomers, conjugates, prodrugs, metabolites, and derivatives
  • any references to darglitazone in this description should be understood as also referring to such salts, solvates, isomers, conjugates, prodrugs, metabolites, and derivatives.
  • Rivoglitazone (5-(4-(6-methoxy-1-methyl-1 H-benzimidazol-2- ylmethoxy)benzyl)thiazolidin-2,4-dione) is disclosed in US Patent Nos. 5,886,014 and 6,706,746 the subject matter of which is hereby incorporated by reference.
  • Rivoglitazone may be used according to the invention in the form of any of its pharmaceutically acceptable salts (e.g, rivoglitazone hydrochloride), solvates, isomers, conjugates, prodrugs, metabolites, and derivatives, any references to rivoglitazone in this description should be understood as also referring to such salts, solvates, isomers, conjugates, prodrugs, metabolites, and derivatives.
  • salts e.g, rivoglitazone hydrochloride
  • solvates isomers, conjugates, prodrugs, metabolites, and derivatives
  • any references to rivoglitazone in this description should be understood as also referring to such salts, solvates, isomers, conjugates, prodrugs, metabolites, and derivatives.
  • Isaglitazone (5-(6-(2-fluorobenzyloxy)-2-naphthyl)-methyl-thiazolidine-2,4- dione) is disclosed in US Patent No. 5,594,016, the subject matter of which is hereby incorporated by reference.
  • Isaglitazone may be used according to the invention in the form of any of its pharmaceutically acceptable salts (e.g., isaglitazone sodium salt), solvates, isomers, conjugates, prodrugs, metabolites, and derivatives, any references to isaglitazone in this description should be understood as also referring to such salts, solvates, isomers, conjugates, prodrugs, metabolites, and derivatives.
  • KRP 297 N-(4-Trifluoromethylbenzyl)-5-(2,4-dioxothiazolidin-5-yl)methyl-2- hydroxybenzamide
  • KRP 297 may be used according to the invention in the form of any of its pharmaceutically acceptable salts, solvates, isomers, conjugates, prodrugs, metabolites, and derivatives, any references to KRP 297 in this description should be understood as also referring to such salts, solvates, isomers, conjugates, prodrugs, metabolites, and derivatives.
  • T 174 (5-((2-(2-naphthyl)-benzoxazol-5-yl)-methyl)thiazolidine-2,4-dione) is disclosed in US Patent No. 4,897,393, the the subject matter of which is hereby incorporated by reference.
  • T 174 may be used according to the invention in the form of any of its pharmaceutically acceptable salts, solvates, isomers, conjugates, prodrugs, metabolites, and derivatives, any references to T 174 in this description should be understood as also referring to such salts, solvates, isomers, conjugates, prodrugs, metabolites, and derivatives.
  • NP 0110 (5-((7-(4-trifluoromethylbenzyloxy)-3-quinolyl)-methyl)thiazolidine- 2,4-dione) is disclosed in US Patent No. 5,693,651, the the subject matter of which is hereby incorporated by reference.
  • NP 0110 may be used according to the invention in the form of any of its pharmaceutically acceptable salts, solvates, isomers, conjugates, prodrugs, metabolites, and derivatives, any references to NP 0110 in this description should be understood as also referring to such salts, solvates, isomers, conjugates, prodrugs, metabolites, and derivatives.
  • salts include, but are not limited to, acid addition salts, such as those made with hydrochloric, methylsulfonic, hydrobromic, hydroiodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, pyruvic, malonic, succinic, fumaric, tartaric, citric, benzoic, carbonic, cinnamic, mandelic, methanesulfonic, ethanesulfonic, hydroxyethanesulfonic, benezenesulfonic, p- toluene sulfonic, cyclohexanesulfamic, salicyclic, p-aminosalicylic, 2-phenoxybenzoic, and 2-acetoxybenzoic acid. All of these salts (or other similar salts) may be prepared by conventional means. The nature of the salt is not critical, provided that it is nontoxic and does not substantially interfere with the desired
  • analog or “derivative” is used herein in the conventional pharmaceutical sense, to refer to a molecule that structurally resembles a reference molecule (such as memantine), but has been modified in a targeted and controlled manner to replace one or more specific substituents of the referent molecule with an alternate substituent, thereby generating a molecule which is structurally similar to the reference molecule.
  • Synthesis and screening of analogs e.g., using structural and/or biochemical analysis, to identify slightly modified versions of a known compound which may have improved or biased traits (such as higher potency and/or selectivity at a specific targeted receptor type, greater ability to penetrate mammalian blood-brain barriers, fewer side effects, etc.) is a drug design approach that is well known in pharmaceutical chemistry.
  • the term "treat” is used herein to mean to relieve or alleviate at least one symptom of a disease in a subject. Within the meaning of the present invention, the term “treat” also denotes to arrest, delay the onset (i.e., the period prior to clinical manifestation of a disease) and/or reduce the risk of developing or worsening a disease. [0043]
  • the term "therapeutically effective” applied to dose or amount refers to that quantity of a compound or pharmaceutical composition that is sufficient to result in a desired activity upon administration to a mammal in need thereof.
  • sub-threshold refers to the amount of an active ingredient inadequate to produce a response, i.e., an amount below the minimum effective amount when the active ingredient is used as monotherapy.
  • sub-optimal in the same context means an amount of an active ingredient that produces a response but not to its full extent, which would be achieved with a higher amount.
  • additive refers to the combined effect of administering two compounds, where the overall response is equal to, or nearly equal to the sum of the responses if the compounds were administered as monotherapy.
  • synergy refers to the combined effect of administering two therapeutic compounds where the overall response is greater than the sum of the two individual effects.
  • synergy also refers to the combined effect of administering an amount of one compound that, when administered as monotherapy, produces no measurable response but, when administered in combination with another therapeutic compound, produces an overall response that is greater than ⁇ that produced by the second compound alone.
  • compositions of the invention refers to molecular entities and other ingredients of such compositions that are physiologically tolerable and do not typically produce untoward reactions when administered to a mammal (e.g., human).
  • pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in mammals, and more particularly in humans.
  • carrier applied to pharmaceutical compositions of the invention refers to a diluent, excipient, or vehicle with which an active substance (e.g., memantine and/or pioglitazone) is administered.
  • Such pharmaceutical carriers can be sterile liquids, such as water, saline solutions, aqueous dextrose solutions, aqueous glycerol solutions, and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences” by A.R. Gennaro, 20 th Edition.
  • the term “about” or “approximately” usually means within 20%, alternatively within 10%, including within 5% of a given value or range. Alternatively, especially in biological systems, the term “about” means within about a log ⁇ i.e., an order of magnitude), including within a factor of two of a given value.
  • compositions comprising a therapeutically effective amount of memantine and/or a therapeutically acceptable amount of a glitazone (for example, pioglitazone).
  • the compositions of the invention may further comprise a carrier or excipient (all pharmaceutically acceptable).
  • the compositions may be formulated for once-a-day administration, twice-a-day administration, or three times a day administration.
  • composition or a single active ingredient of the present invention may be used for the manufacture of a medicament for the treatment of one of the mentioned disorders, wherein the medicament is adapted to or appropriately prepared for a specific administration as disclosed herein (e.g., to once-a-day, twice-a-day administration, or three times a day administration).
  • the package leaflet and/or the patient information contains corresponding information.
  • the dosage form of the compositions may be a solid, semisolid, thin film/flash dose, or liquid formulation according to the following.
  • compositions may be administered orally, topically, parenterally, or mucosally (e.g., buccally, by inhalation, or rectally) in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers.
  • the compositions may be administered orally in the form of a capsule, a tablet, or the like, or as a semi-solid, thin film/flash dose, or liquid formulation (see Remington's Pharmaceutical Sciences, 20 th Edition, by A. R. Gennaro).
  • the compositions may be combined with a non-toxic, pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, sucrose, glucose, mannitol, sorbitol and other reducing and non-reducing sugars, microcrystalline cellulose, calcium sulfate, or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc, or silica, steric acid, sodium stearyl fumarate, glyceryl behenate, calcium stearate, and the like); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate), coloring and flavoring agents, gelatin, sweeteners, natural and synthetic gums (such as acacia), e.g., pregelatinized maize starch,
  • the tablets may be coated with a concentrated sugar solution which may contain e.g., gum arabic, gelatine, talcum, titanium dioxide, and the like.
  • the tablets can be coated with a polymer that dissolves in a readily volatile organic solvent or mixture of organic solvents.
  • the active substances are formulated in immediate-release (IR) or modified-release (MR) tablets. Immediate release solid dosage forms permit the release of most or all of the active ingredient over a short period of time, such as 60 minutes or less, and make rapid absorption of the drug possible (for example, immediate release formulations of memantine are disclosed in US Published Application No. 2006/0002999, the subject matter of which is hereby incorporated by reference).
  • Modified release solid oral dosage forms permit the sustained release of the active ingredient over an extended period of time in an effort to maintain therapeutically effective plasma levels over similarly extended time intervals and/or to modify other pharmacokinetic properties of the active ingredient (for example, modified release formulations of memantine are disclosed in US Published Application No. 2006/0051416, the subject matter of which is hereby incorporated by reference).
  • the active substances may be admixed with e.g., a vegetable oil or poly-ethylene glycol.
  • Hard gelatin capsules may contain granules of the active substances using either the above mentioned excipients for tablets e.g., lactose, saccharose, sorbitol, mannitol, starches (e.g., potato starch, corn starch or amylopectin), cellulose derivatives or gelatine.
  • liquids or semisolids of the drug can be filled into hard gelatine capsules.
  • compositions of the invention can also be introduced in microspheres or microcapsules, e.g., fabricated from polyglycolic acid/lactic acid (PGLA) (see, e.g., U.S. Patents No. 5,814,344; 5,100,669 and 4,849,222; PCT Publications No. WO 95/11010 and WO 93/07861).
  • PGLA polyglycolic acid/lactic acid
  • Biocompatible polymers may be used in achieving controlled release of a drug, include for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polyhydropyrans, polycyanoacrylates, and cross-linked or amphipathic block copolymers of hydrogels.
  • Formulation of the compositions of the invention in a semi-solid or liquid form may also be used.
  • the active ingredient i.e., memantine and/or, for example, pioglitazone
  • the compositions are administered in modified release formulations.
  • Modified release dosage forms provide a means for improving patient compliance and for ensuring effective and safe therapy by reducing the incidence of adverse drug reactions. Compared to immediate release dosage forms, modified release dosage forms can be used to prolong pharmacologic action after administration, and to reduce variability in the plasma concentration of a drug throughout the dosage interval, thereby eliminating or reducing sharp peaks.
  • a modified release form dosage may comprise a core either coated with or containing a drug.
  • the core being is then coated with a release modifying polymer within which the drug is dispersed.
  • the release modifying polymer disintegrates gradually, releasing the drug over time.
  • the outer-most layer of the composition effectively slows down and thereby regulates the diffusion of the drug across the coating layer when the composition is exposed to an aqueous environment, i.e. the gastrointestinal tract.
  • the net rate of diffusion of the drug is mainly dependent on the ability of the gastric fluid to penetrate the coating layer or matrix and on the solubility of the drug itself.
  • compositions are formulated in oral, liquid formulations.
  • Liquid preparations for oral administration can take the form of, for example, solutions, syrups, emulsions or suspensions, or they can be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Preparations for oral administration can be suitably formulated to give controlled or postponed release of the active compound.
  • oral liquid formulations of memantine are described in PCT Application No. PCT/US2004/037026, the subject matter of which is hereby incorporated by reference.
  • compositions may be combined with non-toxic, pharmaceutically acceptable inert carriers (e.g., ethanol, glycerol, water), suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats), emulsifying agents (e.g., lecithin or acacia), non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils), preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid), and the like.
  • inert carriers e.g., ethanol, glycerol, water
  • suspending agents e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats
  • emulsifying agents e.g., lecithin or acacia
  • non-aqueous vehicles e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils
  • Stabilizing agents such as antioxidants (BHA, BHT, propyl gallate, sodium ascorbate, citric acid) can also be added to stabilize the dosage forms.
  • solutions may contain from about 0.2% to about 20% by weight of the active substance, with the balance being sugar and mixture of ethanol, water, glycerol and propylene glycol.
  • such liquid formulations may contain coloring agents, flavoring agents, saccharine and carboxymethyl-cellulose as a thickening agent or other excipients.
  • a therapeutically effective amount of the active substance is administered in an oral solution containing a preservative, a sweetener, a solubilizer, and a solvent.
  • the oral solution may include one or more . buffers, flavorings, or additional excipients.
  • a peppermint or other flavoring is added to the oral liquid formulation.
  • compositions may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, , trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, , trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
  • the dosage unit can be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator can be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
  • Solutions for parenteral applications by injection may be prepared in an aqueous solution of a water-soluble pharmaceutically acceptable salt of the active substances, preferably in a concentration of from about 0.5% to about 10% by weight. These solutions may also contain stabilizing agents and/or buffering agents and may conveniently be provided in various dosage unit ampoules.
  • the formulations of the invention may be delivered parenterally, i.e., by intravenous (i.v.), intracerebroventricular (i.c.v.), subcutaneous (s.c), intraperitoneal (i.p.), intramuscular (i.m.), subdermal (s.d.), or intradermal (i.d.) administration, by direct injection, via, for example, bolus injection or continuous infusion.
  • Formulations for injection can be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
  • the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • the invention also provides a pharmaceutical pack or kit comprising one or more containers containing the active substances (i.e., memantine and/or, for example, pioglitazone) and, optionally, more of the ingredients of the formulation.
  • the compositions are provided as oral solutions (2 mg/ml) for administration with the use of a 2 teaspoon capacity syringe (dosage KORC®).
  • Each oral syringe has blue hatch marks for measurement, with lines on the right side of the syringe (tip down) representing tsp units, and those on the left representing ml units.
  • the optimal therapeutically effective amount may be determined experimentally, taking into consideration the exact mode of administration, from in which the drug is. administered, the indication toward which the administration is directed, the subject involved (e.g., body weight, health, age, sex, etc.), and the preference and experience of the physician or veterinarian in charge.
  • Dosage units for rectal application may be solutions or suspensions or may be prepared in the form of suppositories or retention enemas comprising the active substances in a mixture with a neutral fatty base, or gelatin rectal capsules comprising the active substances in admixture with vegetable oil or paraffin oil.
  • Toxicity and therapeutic efficacy of the compositions of the invention may be determined by standard pharmaceutical procedures in experimental animals, e.g., by determining the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
  • the dose ratio between therapeutic and toxic effects is the therapeutic index and it may be expressed as the ratio LD 5 0/ED 50 .
  • Compositions that exhibit large therapeutic indices are preferred.
  • Suitable daily doses of the active compounds of the invention in therapeutic treatment of humans are about 0.01-10 mg/kg bodyweight on peroral administration and 0.001-10 mg/kg bodyweight on parenteral administration.
  • suitable daily doses of memantine e.g. memantine hydrochloride
  • memantine hydrochloride are within the range from about 1 mg to about 200 mg per day, such as from about 5 mg to about 80 mg, from about 10 mg to about 40 mg, such as 5 mg, 10 mg, 15 mg, or 20 mg, per day.
  • memantine e.g. memantine hydrochloride
  • memantine hydrochloride may be administered as an oral, liquid dosage form, at about 0.5 mg/day, up to a maximum dose of 10 mg/day.
  • Suitable daily doses for glitazones are within the range of from about 1 to about 1000 mg per day.
  • suitable daily dosages for pioglitazone e.g., pioglitazone hydrochloride
  • suitable daily dosages for rosiglitazone are within the range of 1 mg to 100 mg per day, such as from 5 mg to 10 mg per day.
  • Treatment duration may be short-term, e.g., several weeks (for example 8-14 weeks), or long-term until the attending physician deems further administration no longer is necessary.
  • EXAMPLE 1 Evaluation of Memantine in Combination with Pioglitazone for the Treatment of Alzheimer's Disease
  • the objective of this pilot project is to conduct a clinical trial to assess the efficacy of a combination comprising memantine and pioglitazone as a treatment for Alzheimer's disease.
  • Patients treated with a combination comprising memantine and pioglitazone may be expected to demonstrate beneficial therapeutic effects which are substantially greater than the therapeutic effects provided by memantine monotherapy.
  • the primary objective of this study is to investigate the effect of memantine in combination with pioglitazone on disease progression (as measured by SIB and ADCS-ADL) in patients suffering from Alzheimer's disease.
  • Presence of a caregiver (friend or relative) who can assume responsibility for medication compliance, can accompany the patient to all visits, and rate patient's condition
  • MMSE Mini Mental State Exam Score
  • Visit 1 Initial screening: After signing the consent form, the subject undergoes an evaluation, in which primary and secondary parameters are evaluated. Patient eligibility for study is evaluated via review of inclusion/exclusion criteria with the subject and caregiver.
  • Visit 2 (baseline): Subject is evaluated for study eligibility based on a review of the inclusion/exclusion criteria. Study procedures as well as concomitant medications are reviewed with the subject and caregiver. Subject is enrolled in the study and medication is dispensed as described below.
  • Visits 3-6 These visits occur four, eight, twelve, and eighteen weeks after baseline. Review of concomitant medications as well as the occurrence of adverse events since the last visit are conducted with subject and caregiver. Primary and secondary parameters are evaluated. Medication is dispensed as described below.
  • Visit 7 This visit occurs twenty-four weeks after baseline. Change from baseline in SIB and ADCS-ADL Inventory scores as well as secondary parameters are evaluated.
  • Memantine hydrochloride is administered as commercially available tablets containing 5 mg memantine at a dose of 20 mg per day.
  • Pioglitazone hydyrochloride is adminstered as commercially available tablets containing 15 mg pioglitazone at a dose of 15-45 mg per day. Placebo is administered as matching tablets. Efficacy
  • Memantine/pioglitazone combination treatment provides beneficial effects based on measures of cognition, daily functioning, and clinical global status which are substantially greater than the beneficialal effects associated with memantine monotherapy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur des combinaisons comprenant de la mémantine et une glitazone et sur l'utilisation de telles combinaisons dans le traitement de troubles neurodégénératifs et/ou pour fournir une neuroprotection.
PCT/EP2008/008400 2007-10-05 2008-10-03 Thérapie de combinaison utilisant la mémantine et les glitazones WO2009043593A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99797907P 2007-10-05 2007-10-05
US60/997,979 2007-10-05
EP07253960 2007-10-05
EP07253960.4 2007-10-05

Publications (1)

Publication Number Publication Date
WO2009043593A1 true WO2009043593A1 (fr) 2009-04-09

Family

ID=38924374

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/008400 WO2009043593A1 (fr) 2007-10-05 2008-10-03 Thérapie de combinaison utilisant la mémantine et les glitazones

Country Status (1)

Country Link
WO (1) WO2009043593A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014093114A1 (fr) * 2012-12-11 2014-06-19 Metabolic Solutions Development Company Llc Thiazolidinediones épargnant les ppar et associations pour le traitement de maladies neurodégénératives
WO2019193347A3 (fr) * 2018-04-04 2020-01-09 Wren Therapeutics Limited Thérapie pour une maladie de mauvais repliement de protéines
US12274703B2 (en) 2017-12-21 2025-04-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
WO1999025346A1 (fr) * 1997-11-19 1999-05-27 Takeda Chemical Industries, Ltd. Nouvel inhibiteur d'apoptose
WO2007038112A2 (fr) * 2005-09-22 2007-04-05 Sb Pharmco Puerto Rico Inc. Composition pharmaceutique conçue pour ameliorer la fonction cognitive

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
WO1999025346A1 (fr) * 1997-11-19 1999-05-27 Takeda Chemical Industries, Ltd. Nouvel inhibiteur d'apoptose
WO2007038112A2 (fr) * 2005-09-22 2007-04-05 Sb Pharmco Puerto Rico Inc. Composition pharmaceutique conçue pour ameliorer la fonction cognitive

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; January 2006 (2006-01-01), DORAISWAMY P MURALI ET AL: "Pharmacological strategies for the prevention of Alzheimer's disease.", XP002465610, Database accession no. NLM16370917 *
EXPERT OPINION ON PHARMACOTHERAPY JAN 2006, vol. 7, no. 1, January 2006 (2006-01-01), pages 1 - 10, ISSN: 1744-7666 *
GELDMACHER D S ET AL: "P1-397 Pioglitazone in Alzheimer's disease: rationale and clinical trial design", NEUROBIOLOGY OF AGING, TARRYTOWN, NY, US, vol. 25, July 2004 (2004-07-01), pages S211 - S212, XP004625323, ISSN: 0197-4580 *
LIU ET AL: "Nanoparticle and other metal chelation therapeutics in Alzheimer disease", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR BASIS OF DISEASE, AMSTERDAM, NL, vol. 1741, no. 3, 25 September 2005 (2005-09-25), pages 246 - 252, XP005088403, ISSN: 0925-4439 *
STEELE ET AL: "Healthy nutrition and selected micronutrients can delay the cognitive decline in the elderly", EXPERIMENTAL GERONTOLOGY, ELSEVIER SCIENCE, OXFORD, GB, vol. 42, no. 1-2, 21 December 2006 (2006-12-21), pages 8 - 9, XP005809971, ISSN: 0531-5565 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014093114A1 (fr) * 2012-12-11 2014-06-19 Metabolic Solutions Development Company Llc Thiazolidinediones épargnant les ppar et associations pour le traitement de maladies neurodégénératives
US12274703B2 (en) 2017-12-21 2025-04-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
WO2019193347A3 (fr) * 2018-04-04 2020-01-09 Wren Therapeutics Limited Thérapie pour une maladie de mauvais repliement de protéines

Similar Documents

Publication Publication Date Title
US20210294011A1 (en) Glutamate agents in the treatment of mental disorders
US9119843B2 (en) Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions
US20100099700A1 (en) Hydrogenated pyrido (4,3-b) indoles for treating amyotrophic lateral sclerosis (als)
US20090081259A1 (en) 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
KR20100052557A (ko) 이명 치료를 위한 간격 치료요법
AU2008281016B2 (en) Novel combinations of neramexane for the treatment of neurodegenerative disorders
US20140107212A1 (en) 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
US20100152249A1 (en) Compositons and method for treatment of mood and cognitive impairments
CN101272805A (zh) 包含PPARγ激动剂的药物组合物
WO2009043593A1 (fr) Thérapie de combinaison utilisant la mémantine et les glitazones
US20050004179A1 (en) Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
CA3046297A1 (fr) Utilisation de composes de carbamate pour la prevention, l'attenuation ou le traitement d'un trouble bipolaire
US20110207793A1 (en) 1-aminocyclohexane derivatives for the treatment of sleep disorders.
JP6084931B2 (ja) ストレス又は急性聴力損失に関連する耳鳴の治療又は予防のためのネラメキサン
JP2011520905A (ja) 向知性剤としてのムスカリンアゴニスト

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08836262

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08836262

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载